Introduction: Contemporary heart valve substitutes allow satisfactory replacement option for the older patients (>60 years). For the paediatric, adolescent and young adult population current heart valve replacements lack the ability to grow and regenerate, requiring multiple repeat surgeries. Partial heart transplantation (PHT) represents a new heart valve replacement method overcoming the limitations of current valve substitutes by providing a living heart valve. The limitation of PHT is the short shelf life (48hours) from procurement to implantation. Methods: Our group has developed an ice-free cryopreservation (IFC) technique (vitrification) to preserve vital extracellular matrix architecture in human heart valves for transplantation. Shortcoming of the original vitrification protocol was a high cytotoxicity of the required chemical supplements. Results: We have developed a modified vitrification protocol with adjusted chemical supplements maintaining ECM integrity and viability allowing long-term storage of ovine and porcine PHT valves. Conclusion: PHT combined with a modified IFC protocol offers an attractive pathway to overcome contemporary limitations of allograft heart valves. This next generation of homovitals allows lomg-term storage and preservation of crucial ECM integrity and cellular viability